Jupiter Neurosciences (NASDAQ:JUNS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Jupiter Neurosciences (NASDAQ:JUNS) from a strong sell rating to a sell rating in a research report sent to investors on Sunday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jupiter Neurosciences presently has an average rating of “Sell”.

Jupiter Neurosciences Stock Performance

Shares of NASDAQ JUNS opened at $5.06 on Friday. The stock has a market cap of $3.90 million, a PE ratio of -0.26 and a beta of 1.99. Jupiter Neurosciences has a fifty-two week low of $4.56 and a fifty-two week high of $137.96. The stock has a fifty day moving average of $12.44 and a 200-day moving average of $24.32.

Jupiter Neurosciences (NASDAQ:JUNS) last released its quarterly earnings data on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.40 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vestor Capital LLC grew its position in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares in the last quarter. Yorkville Advisors Global LP purchased a new stake in shares of Jupiter Neurosciences in the fourth quarter worth $135,000. Finally, Allen Capital Group LLC purchased a new stake in shares of Jupiter Neurosciences in the fourth quarter worth $31,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.